Gilead Sciences, Inc. $GILD Shares Bought by Woodline Partners LP

Woodline Partners LP grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 750,516 shares of the biopharmaceutical company’s stock after buying an additional 15,823 shares during the quarter. Gilead Sciences accounts for 0.5% of Woodline Partners LP’s investment portfolio, making the stock its 27th largest position. Woodline Partners LP owned about 0.06% of Gilead Sciences worth $84,095,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC purchased a new position in Gilead Sciences in the 4th quarter valued at about $215,000. Focus Partners Wealth boosted its holdings in Gilead Sciences by 14.7% in the 4th quarter. Focus Partners Wealth now owns 117,736 shares of the biopharmaceutical company’s stock worth $10,875,000 after buying an additional 15,048 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $1,744,000. Finally, Jacobs Levy Equity Management Inc. increased its stake in Gilead Sciences by 27.6% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 648,386 shares of the biopharmaceutical company’s stock worth $59,891,000 after buying an additional 140,095 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.7%

NASDAQ GILD opened at $115.88 on Tuesday. The business’s fifty day simple moving average is $113.69 and its 200-day simple moving average is $109.95. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a market cap of $143.79 billion, a PE ratio of 23.08, a P/E/G ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $78.36 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Ratings Changes

Several research firms have recently weighed in on GILD. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $115.39.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares of the company’s stock, valued at $18,977,838.30. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,371,330. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.